login
login

Europe Daily Bulletin No. 8286

30 August 2002
Contents Publication in full By article 30 / 34
ECONOMIC INTERPENETRATION / (eu) pharmaceuticals

The Swiss group NOVARTIS is to acquire the Slovenian laboratory LEK (turnover $198 million during the first half of 2002), specialised in the manufacture of generic medicines. The amount of the operation is expected to be EUR 765 million, according to LEK's current stock exchange capitalisation.

Contents

THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION